Corcept Therapeutics Shares Jump as Relacorilant Shows Promise in Ovarian Cancer Survival Rates
Corcept Therapeutics experienced a notable 45% stock increase following positive Phase 3 trial results for relacorilant in treating platinum-resistant ovarian cancer. The ROSELLA trial demonstrated a significant survival benefit when relacorilant was combined with nab-paclitaxel chemotherapy compared to chemotherapy alone. The treatment was well to…